CA2697621C - Method of efficiently establishing induced pluripotent stem cells - Google Patents
Method of efficiently establishing induced pluripotent stem cells Download PDFInfo
- Publication number
- CA2697621C CA2697621C CA2697621A CA2697621A CA2697621C CA 2697621 C CA2697621 C CA 2697621C CA 2697621 A CA2697621 A CA 2697621A CA 2697621 A CA2697621 A CA 2697621A CA 2697621 C CA2697621 C CA 2697621C
- Authority
- CA
- Canada
- Prior art keywords
- cells
- oct3
- cell
- myc
- sox2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title claims abstract description 7
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 78
- 230000008672 reprogramming Effects 0.000 claims abstract description 75
- 230000001146 hypoxic effect Effects 0.000 claims abstract description 71
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 50
- 238000012258 culturing Methods 0.000 claims abstract description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 113
- 229910052760 oxygen Inorganic materials 0.000 claims description 110
- 239000001301 oxygen Substances 0.000 claims description 110
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 106
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 76
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 71
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 71
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 69
- 239000000126 substance Substances 0.000 claims description 59
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 52
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 229960000604 valproic acid Drugs 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 description 373
- 108090000623 proteins and genes Proteins 0.000 description 86
- 239000005090 green fluorescent protein Substances 0.000 description 48
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 45
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 45
- 241000699666 Mus <mouse, genus> Species 0.000 description 41
- 108020004414 DNA Proteins 0.000 description 40
- 208000015181 infectious disease Diseases 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 30
- 239000002609 medium Substances 0.000 description 27
- 239000013598 vector Substances 0.000 description 27
- 238000004113 cell culture Methods 0.000 description 21
- 210000000130 stem cell Anatomy 0.000 description 21
- 238000012546 transfer Methods 0.000 description 17
- 239000013604 expression vector Substances 0.000 description 16
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- -1 13111-tubulin Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 206010043276 Teratoma Diseases 0.000 description 10
- 210000000981 epithelium Anatomy 0.000 description 10
- 101150111214 lin-28 gene Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000010186 staining Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 229950010131 puromycin Drugs 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000007954 hypoxia Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 6
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000013600 plasmid vector Substances 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108091027967 Small hairpin RNA Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 4
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 101150099612 Esrrb gene Proteins 0.000 description 4
- 101150112014 Gapdh gene Proteins 0.000 description 4
- 101000971801 Homo sapiens KH domain-containing protein 3 Proteins 0.000 description 4
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 4
- 102100021450 KH domain-containing protein 3 Human genes 0.000 description 4
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 4
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 4
- 101100404103 Mus musculus Nanog gene Proteins 0.000 description 4
- 101100137157 Mus musculus Pou5f1 gene Proteins 0.000 description 4
- 101100094847 Mus musculus Slc22a3 gene Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012136 culture method Methods 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 3
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 101100310650 Mus musculus Sox18 gene Proteins 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000013256 coordination polymer Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000002242 embryoid body Anatomy 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 230000017105 transposition Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 101100257372 Caenorhabditis elegans sox-3 gene Proteins 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100036912 Desmin Human genes 0.000 description 2
- 108010044052 Desmin Proteins 0.000 description 2
- 102100037124 Developmental pluripotency-associated 5 protein Human genes 0.000 description 2
- 101150033269 ESRRG gene Proteins 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 2
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 2
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- 101000669432 Homo sapiens Transducin-like enhancer protein 1 Proteins 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 2
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 2
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 2
- 101100257376 Mus musculus Sox3 gene Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 101150001847 Sox15 gene Proteins 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 101710101305 Transducin-like enhancer protein 1 Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000013127 Vimentin Human genes 0.000 description 2
- 108010065472 Vimentin Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000005045 desmin Anatomy 0.000 description 2
- 230000000431 effect on proliferation Effects 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 102000048971 human GDF3 Human genes 0.000 description 2
- 102000053563 human MYC Human genes 0.000 description 2
- 102000054063 human TLE1 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000007959 normoxia Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001988 somatic stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 210000005048 vimentin Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical group C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- JUNHQBJCWZVSAT-BQYQJAHWSA-N (e)-n-hydroxy-3-[1-methyl-4-(4-methylbenzoyl)pyrrol-2-yl]prop-2-enamide Chemical compound C1=CC(C)=CC=C1C(=O)C1=CN(C)C(\C=C\C(=O)NO)=C1 JUNHQBJCWZVSAT-BQYQJAHWSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- GEBBCNXOYOVGQS-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(hydroxyamino)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](NO)O1 GEBBCNXOYOVGQS-BNHYGAARSA-N 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 101150019028 Antp gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 102000001267 GSK3 Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000011787 Histone Methyltransferases Human genes 0.000 description 1
- 108010036115 Histone Methyltransferases Proteins 0.000 description 1
- 101000893552 Homo sapiens Embryonic growth/differentiation factor 1 Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 1
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101000804949 Mus musculus Developmental pluripotency-associated protein 2 Proteins 0.000 description 1
- 101100043062 Mus musculus Sox7 gene Proteins 0.000 description 1
- 108091057508 Myc family Proteins 0.000 description 1
- 102220595793 Myc proto-oncogene protein_T58A_mutation Human genes 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 101150012532 NANOG gene Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101150071661 SLC25A20 gene Proteins 0.000 description 1
- 101150024531 Slc7a1 gene Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 1
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 230000001155 adrenomedullary effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 108010025307 buforin II Proteins 0.000 description 1
- 101150102633 cact gene Proteins 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- FMURUEPQXKJIPS-UHFFFAOYSA-N n-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C=12C=C(OC)C(OC)=CC2=NC(N2CCN(C)CCC2)=NC=1NC(CC1)CCN1CC1=CC=CC=C1 FMURUEPQXKJIPS-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- 102220283058 rs1555526832 Human genes 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003172 sustentacular cell Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8484208P | 2008-07-30 | 2008-07-30 | |
| US61/084,842 | 2008-07-30 | ||
| US14117708P | 2008-12-29 | 2008-12-29 | |
| US61/141,177 | 2008-12-29 | ||
| US20393108P | 2008-12-30 | 2008-12-30 | |
| US61/203,931 | 2008-12-30 | ||
| PCT/JP2009/063906 WO2010013845A1 (en) | 2008-07-30 | 2009-07-30 | Method of efficiently establishing induced pluripotent stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2697621A1 CA2697621A1 (en) | 2010-02-04 |
| CA2697621C true CA2697621C (en) | 2017-01-17 |
Family
ID=41610532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2697621A Active CA2697621C (en) | 2008-07-30 | 2009-07-30 | Method of efficiently establishing induced pluripotent stem cells |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9528092B2 (OSRAM) |
| EP (1) | EP2307539B1 (OSRAM) |
| JP (1) | JP5562231B2 (OSRAM) |
| KR (1) | KR101685209B1 (OSRAM) |
| CN (2) | CN101848994A (OSRAM) |
| CA (1) | CA2697621C (OSRAM) |
| WO (1) | WO2010013845A1 (OSRAM) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010042490A1 (en) * | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
| US10328103B2 (en) | 2009-01-03 | 2019-06-25 | Ray C. Wasielewski | Medical treatment composition comprising mammalian dental pulp stem cells |
| US8470308B2 (en) * | 2009-01-03 | 2013-06-25 | Ray C. Wasielewski | Enhanced medical implant comprising disrupted tooth pulp and tooth particles |
| JP5637354B2 (ja) * | 2009-03-30 | 2014-12-10 | 独立行政法人産業技術総合研究所 | 精製転写因子の調製法と細胞導入技術 |
| AU2010279913B2 (en) | 2009-08-07 | 2016-04-28 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| EP2470664A4 (en) | 2009-08-27 | 2013-01-16 | Synaptic Res Llc | NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS |
| WO2011032166A2 (en) * | 2009-09-14 | 2011-03-17 | The Johns Hopkins University | Reprogramming blood cells to pluripotent and multipotent stem cells |
| US20120276070A1 (en) * | 2009-11-17 | 2012-11-01 | Vitro Diagnositics, Inc. | Induced Pluripotent Stem Cells and Related Methods |
| CA2802249A1 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | Generation of induced pluripotent stem cells from small volumes of peripheral blood |
| WO2011160128A2 (en) * | 2010-06-18 | 2011-12-22 | Cellular Dynamics International, Inc. | Cardiomyocyte medium with dialyzed serum |
| JP6029137B2 (ja) | 2010-12-03 | 2016-11-24 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
| KR20200113286A (ko) | 2010-12-22 | 2020-10-06 | 페이트 세러퓨틱스, 인코포레이티드 | 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼 |
| EP3608423A1 (en) | 2011-07-25 | 2020-02-12 | Kyoto University | Method for screening induced pluripotent stem cells |
| US20140227780A1 (en) * | 2011-10-03 | 2014-08-14 | Nissan Chemical Industries, Ltd. | Method for producing megakaryocytes and/or platelets from pluripotent stem cells |
| JP6162604B2 (ja) | 2011-10-21 | 2017-07-12 | 国立大学法人京都大学 | 層流による多能性維持単一分散細胞培養法 |
| JP5999658B2 (ja) | 2011-11-25 | 2016-09-28 | 国立大学法人京都大学 | 多能性幹細胞の培養方法 |
| KR101930718B1 (ko) | 2012-03-28 | 2018-12-19 | 가부시키가이샤 쿠오리맨 앤 코. | 불사화 줄기세포 및 그 생산물을 유효 성분으로 하는 의약 조성물 및 의약 제제 |
| JP6381442B2 (ja) | 2012-05-23 | 2018-08-29 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
| JPWO2013183718A1 (ja) * | 2012-06-06 | 2016-02-01 | 国立大学法人京都大学 | スクリーニング方法、タンパク質の不安定性及び／又は安定性を誘導する物質、及び、タンパク質の活性評価 |
| EP2948776B8 (en) | 2013-01-25 | 2020-02-26 | Xcell Biosciences, Inc. | Methods, compositions, kits, and systems for selective enrichment of target cells |
| EP2955223B1 (en) | 2013-02-08 | 2019-12-18 | Kyoto University | Production methods for megakaryocytes and platelets |
| EP2966163B1 (en) | 2013-03-06 | 2018-01-17 | Kyoto University | Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells |
| US9790468B2 (en) | 2013-03-15 | 2017-10-17 | Avita Iinternational Ltd. | Multifunctional immature dental pulp stem cells and therapeutic applications |
| WO2014148646A1 (ja) | 2013-03-21 | 2014-09-25 | 国立大学法人京都大学 | 神経分化誘導用の多能性幹細胞 |
| EP2980207B1 (en) | 2013-03-25 | 2018-12-05 | Foundation for Biomedical Research and Innovation at Kobe | Cell sorting method |
| EP2985344B1 (en) | 2013-04-12 | 2018-07-18 | Kyoto University | Method for inducing alveolar epithelium progenitor cells |
| US9822342B2 (en) | 2013-05-14 | 2017-11-21 | Kyoto University | Method of efficiently inducing cardiomyocytes |
| JP6378183B2 (ja) | 2013-08-07 | 2018-08-22 | 国立大学法人京都大学 | 膵ホルモン産生細胞の製造法 |
| JP6558580B2 (ja) | 2013-09-05 | 2019-08-14 | 国立大学法人京都大学 | 新規ドーパミン産生神経前駆細胞の誘導方法 |
| JP6635505B2 (ja) | 2013-11-01 | 2020-01-29 | 国立大学法人京都大学 | 新規軟骨細胞誘導方法 |
| FR3016372B1 (fr) * | 2014-01-13 | 2018-01-19 | Centre Leon Berard | Procede de preparation de cellules pluripotentes induites |
| CN106102754B (zh) * | 2014-01-24 | 2020-04-17 | 石匠株式会社 | 癌治疗用医药组合物以及将该组合物作为有效成分的癌治疗用医药制剂 |
| CN104894060B (zh) * | 2014-03-03 | 2018-11-06 | 中国科学院上海生命科学研究院 | 诱导体细胞转分化为神经干细胞的方法及其应用 |
| KR102460549B1 (ko) * | 2014-03-04 | 2022-10-28 | 페이트 세러퓨틱스, 인코포레이티드 | 개선된 재프로그래밍 방법 및 세포 배양 플랫폼 |
| EP3170897B1 (en) | 2014-07-18 | 2020-05-13 | Kyoto University | Method for inducing t cells for immunocytotherapy from pluripotent stem cells |
| EP3862425A1 (en) * | 2015-07-29 | 2021-08-11 | Hadasit Medical Research Services and Development Ltd. | Large scale production of retinal pigment epithelial cells |
| KR20250007036A (ko) | 2015-10-16 | 2025-01-13 | 페이트 세러퓨틱스, 인코포레이티드 | 기저 상태 다능성의 유도 및 유지를 위한 플랫폼 |
| WO2017183736A1 (ja) | 2016-04-22 | 2017-10-26 | 国立大学法人京都大学 | ドーパミン産生神経前駆細胞の製造方法 |
| WO2017223199A1 (en) * | 2016-06-22 | 2017-12-28 | Xcell Biosciences, Inc. | Methods for increasing cell culture transfection efficiency and cellular reprogramming |
| EP4595951A3 (en) | 2016-11-10 | 2025-08-27 | ViaCyte, Inc. | Pdx1 pancreatic endoderm cells in cell delivery devices |
| JP7285015B2 (ja) | 2018-07-19 | 2023-06-01 | 国立大学法人京都大学 | 多能性幹細胞由来の板状軟骨およびその製造方法 |
| WO2020022261A1 (ja) | 2018-07-23 | 2020-01-30 | 国立大学法人京都大学 | 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法 |
| EP3900787A4 (en) | 2018-12-21 | 2022-02-23 | Kyoto University | LUBRICIN-LOCALIZED CARTILE-LIKE TISSUE, METHOD OF MANUFACTURE THEREOF AND COMPOSITION THEREOF FOR TREATMENT OF ARTICULATE-CARTILAGE DEFECTS |
| WO2020227677A1 (en) * | 2019-05-09 | 2020-11-12 | Figene, Llc | Fibroblast generated patient-specific vaccines |
| EP3969571A4 (en) | 2019-05-14 | 2023-05-24 | Aleph Farms Ltd. | AGGREGATES OF PLURIPOTENT CELLS AND THEIR USE |
| WO2021117886A1 (ja) | 2019-12-12 | 2021-06-17 | 国立大学法人千葉大学 | 巨核球および血小板を含む凍結乾燥製剤 |
| JP7429294B2 (ja) | 2020-07-13 | 2024-02-07 | 国立大学法人京都大学 | 骨格筋前駆細胞及びその精製方法、筋原性疾患を治療するための組成物、並びに骨格筋前駆細胞を含む細胞群の製造方法 |
| EP4180514A4 (en) | 2020-07-20 | 2024-09-04 | Aichi Medical University | COMPOSITION FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, MEDIUM FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, METHOD FOR MAINTENANCE CULTURE IN UNDIFFERENTIATED STATE OF PLURIPOTENT CELLS, AND METHOD FOR PRODUCING PLURIPOTENT CELLS |
| EP4477746A1 (en) | 2022-02-09 | 2024-12-18 | Sumitomo Pharma Co., Ltd. | Method for assessing differentiation potential of cells in culture broth in differentiation of pluripotent stem cells into neural cells of midbrain floor plate region |
| WO2024248017A1 (ja) | 2023-05-29 | 2024-12-05 | 国立研究開発法人理化学研究所 | 心筋細胞を成熟させる方法及び成熟した心筋細胞の製造方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999020741A1 (en) | 1997-10-23 | 1999-04-29 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
| US20020090722A1 (en) * | 2000-06-15 | 2002-07-11 | Tanja Dominko | Pluripotent mammalian cells |
| PT1572984E (pt) | 2002-12-16 | 2016-06-03 | Technion Res & Dev Foundation | Sistema de cultura para células estaminais embrionárias humanas sem células alimentadoras e sem xeno |
| WO2006019366A1 (en) | 2003-03-28 | 2006-02-23 | Wisconsin Alumni Research Foundation | Physiochemical culture conditions for embryonic stem cells |
| GB2432835B (en) | 2004-09-08 | 2009-04-08 | Wisconsin Alumni Res Found | Culturing human embryonic stem cells |
| US20060275899A1 (en) | 2004-12-30 | 2006-12-07 | Stemlifeline, Inc. | Methods and compositions relating to embryonic stem cell lines |
| ZA200804673B (en) | 2005-12-13 | 2009-11-25 | Univ Kyoto | Nuclear reprogramming factor |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| CN101605885B (zh) | 2007-01-04 | 2013-03-27 | 卡尔·特吕格瓦松 | 能够使多能干细胞增殖的组合物及方法 |
| WO2008118820A2 (en) * | 2007-03-23 | 2008-10-02 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| US20120282229A1 (en) | 2007-08-01 | 2012-11-08 | Christian Kannemeier | Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state |
| WO2009073523A2 (en) | 2007-11-29 | 2009-06-11 | Children's Hospital Of Orange County | De-differentiation of human cells |
| WO2009111087A1 (en) | 2008-03-07 | 2009-09-11 | Worcester Polytechnic Institute | Novel use of basic fibroblast growth factor in the de-differentiation of animal connective tissue cells |
| US20100279404A1 (en) | 2008-05-02 | 2010-11-04 | Shinya Yamanaka | Method of nuclear reprogramming |
| WO2009142717A2 (en) | 2008-05-19 | 2009-11-26 | President And Fellows Of Harvard College | Methods and products for dedifferentiation of cells |
| JP5340265B2 (ja) | 2008-06-27 | 2013-11-13 | 国立大学法人京都大学 | 効率的な人工多能性幹細胞の樹立方法 |
| EP2333050A4 (en) | 2008-09-04 | 2013-07-03 | Riken | IPS CELLS FROM B-CELLS AND ITS APPLICATION |
| US8945922B2 (en) | 2008-09-08 | 2015-02-03 | Riken | Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor α-chain region rearranged to uniform Va-Ja in a NKT-cell specific way |
| CN101492676B (zh) * | 2008-09-16 | 2011-02-16 | 中国科学院广州生物医药与健康研究院 | 用脑膜细胞生成诱导的多能性干细胞的方法及其用途 |
| AU2010279913B2 (en) | 2009-08-07 | 2016-04-28 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
-
2009
- 2009-07-30 CN CN200980100065A patent/CN101848994A/zh active Pending
- 2009-07-30 CN CN201611216942.9A patent/CN107012123A/zh active Pending
- 2009-07-30 US US12/672,222 patent/US9528092B2/en active Active
- 2009-07-30 CA CA2697621A patent/CA2697621C/en active Active
- 2009-07-30 KR KR1020107002641A patent/KR101685209B1/ko active Active
- 2009-07-30 WO PCT/JP2009/063906 patent/WO2010013845A1/en not_active Ceased
- 2009-07-30 EP EP09803075.2A patent/EP2307539B1/en active Active
- 2009-07-30 JP JP2010506476A patent/JP5562231B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107012123A (zh) | 2017-08-04 |
| WO2010013845A1 (en) | 2010-02-04 |
| JP2011529329A (ja) | 2011-12-08 |
| CN101848994A (zh) | 2010-09-29 |
| EP2307539A1 (en) | 2011-04-13 |
| CA2697621A1 (en) | 2010-02-04 |
| KR20110036523A (ko) | 2011-04-07 |
| JP5562231B2 (ja) | 2014-07-30 |
| US20110039338A1 (en) | 2011-02-17 |
| EP2307539B1 (en) | 2014-11-19 |
| KR101685209B1 (ko) | 2016-12-09 |
| EP2307539A4 (en) | 2012-10-24 |
| US9528092B2 (en) | 2016-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2697621C (en) | Method of efficiently establishing induced pluripotent stem cells | |
| US8951801B2 (en) | Method for making IPS cells | |
| US8927277B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| CA2695522C (en) | Method of nuclear reprogramming | |
| US9637732B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| US10077429B2 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| AU2008360135A1 (en) | Efficient method for establishing induced pluripotent stem cells | |
| EP2480657B1 (en) | Method of efficiently establishing induced pluripotent stem cells | |
| WO2017010080A1 (ja) | 高品質なｉＰＳ細胞の製造方法 | |
| WO2011055851A1 (en) | Method of efficiently establishing induced pluripotent stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140723 |